MRC Technology joins project UTILE to enable medical breakthroughs from European funded research
MRC Technology is committed to ensuring that promising medical research is protected and progressed to benefit patients.…
MRC Technology is committed to ensuring that promising medical research is protected and progressed to benefit patients.…
MRC Technology has appointed Steve Visscher CBE to its board of trustees.
Cancer Research UK, Cancer Research Technology and MRC Technology are joining forces to identify and validate novel drug discovery targets that could lead to new immunotherapy treatments.
Edinburgh, Scotland, 17 January 2017: MRC Technology, an independent medical research charity, has announced the relocation of…
MRC Technology has announced the relocation of its Centre for Diagnostics Development (CDD) to Nine, Edinburgh BioQuarter. The move forms part of the charity’s investment of over £7million over the next five years to further its work accelerating diagnostic research into the clinic.
New research consortium aims to identify opportunities for drug discovery through the innovative use of antibodies in structure-based drug discovery and design.
A charity-industry collaboration has launched an initiative to find new epigenetic drug treatments to improve the lives of millions of people affected by respiratory diseases every year.
MRC Technology has monetised a portion of its royalty interest in a leading cancer drug, pembrolizumab (marketed by Merck & Co., Inc. as Keytruda®) with a private equity fund managed by DRI Capital (DRI) for US $150M (£115.6M).
MRC Technology and Keio University School will collaborate to identify promising antibody and small molecule research and translate them into early stage assets.